SRR6013515
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.470
- E2F_TARGETS+0.450
- G2M_CHECKPOINT+0.400
- MYC_TARGETS_V1+0.370
- MTORC1_SIGNALING+0.340
- OXIDATIVE_PHOSPHORYLATION+0.310
- MYC_TARGETS_V2+0.270
- PROTEIN_SECRETION+0.260
- INTERFERON_GAMMA_RESPONSE+0.240
- PI3K_AKT_MTOR_SIGNALING+0.240
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.540
- ANGIOGENESIS-0.420
- TNFA_SIGNALING_VIA_NFKB-0.390
- MYOGENESIS-0.350
- COAGULATION-0.320
- APICAL_JUNCTION-0.300
- KRAS_SIGNALING_UP-0.280
- HYPOXIA-0.270
- UV_RESPONSE_DN-0.250
- TGF_BETA_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613729 | — | E | 0.895 |
| 2 | SRR975555 | — | — | 0.892 |
| 3 | TCGA-AO-A03O-01A-11R-A00Z-07 | — | C | 0.878 |
| 4 | TCGA-18-3419-01A-01R-0980-07 | — | cohortSQ1 | 0.878 |
| 5 | TCGA-BH-A18L-01A-32R-A12D-07 | — | B | 0.875 |
| 6 | TCGA-A2-A0CW-01A-21R-A115-07 | — | B | 0.872 |
| 7 | SRR15030853 | — | — | 0.867 |
| 8 | TCGA-58-A46M-01A-11R-A24H-07 | — | cohortSQ2 | 0.866 |
| 9 | SRR11296797 | — | — | 0.862 |
| 10 | TCGA-C8-A12U-01A-11R-A115-07 | — | B | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.310 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.270 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.110 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |